South Korea Antibody Drug Conjugates Contract Manufacturing Market Size & Outlook
Related Markets
South Korea antibody drug conjugates contract manufacturing market highlights
- The South Korea antibody drug conjugates contract manufacturing market generated a revenue of USD 234.2 million in 2024 and is expected to reach USD 462.5 million by 2030.
- The South Korea market is expected to grow at a CAGR of 12% from 2025 to 2030.
- In terms of segment, myeloma was the largest revenue generating condition in 2024.
- Myeloma is the most lucrative condition segment registering the fastest growth during the forecast period.
Antibody drug conjugates contract manufacturing market data book summary
| Market revenue in 2024 | USD 234.2 million |
| Market revenue in 2030 | USD 462.5 million |
| Growth rate | 12% (CAGR from 2025 to 2030) |
| Largest segment | Myeloma |
| Fastest growing segment | Myeloma |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloma, Lymphoma, Breast Cancer |
| Key market players worldwide | Sterling Check Corp, Recipharm, Lonza Group Ltd, Catalent Inc, Sartorius AG, WuXi Biologics (Cayman) Inc, Samsung BioLogics, Piramal Healthcare, AbbVie Inc, Merck KGaA |
Other key industry trends
- In terms of revenue, South Korea accounted for 2.6% of the global antibody drug conjugates contract manufacturing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China antibody drug conjugates contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,650.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Contract Manufacturing Market Scope
Antibody Drug Conjugates Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Piramal Healthcare | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.piramalpharmasolutions.com |
| Sterling Check Corp | View profile | 5700 | 6150 Oak Tree Boulevard, Suite 490, Independence, OH, United States, 44131 | https://www.sterlingcheck.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Sartorius AG | View profile | 14338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | https://www.sartorius.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
South Korea antibody drug conjugates contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates contract manufacturing market will help companies and investors design strategic landscapes.
Myeloma was the largest segment with a revenue share of 55.55% in 2024. Horizon Databook has segmented the South Korea antibody drug conjugates contract manufacturing market based on myeloma, lymphoma, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Supportive government reforms are anticipated to propel market growth. For instance, in 2020, South Korea’s government announced an investment of nearly USD 1.7 billion to promote the biotechnology & biopharmaceutical industries and encourage biopharmaceutical R&D & manufacturing.
This strategy was expected to include an increase in tax credits for facility and R&D investments, which can positively impact the market. Multiple biopharmaceutical companies in the country are actively involved in developing ADCs.
For instance, in July 2022, South Korea’s biopharmaceutical LegoChem Biosciences, Inc. (LCB) signed a research collaboration with Glycotope GmbH, under which, LCB was to develop ADCs for the latter company.
Reasons to subscribe to South Korea antibody drug conjugates contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Korea antibody drug conjugates contract manufacturing market databook
-
Our clientele includes a mix of antibody drug conjugates contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea antibody drug conjugates contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into South Korea antibody drug conjugates contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Korea antibody drug conjugates contract manufacturing market size, by condition, 2018-2030 (US$M)
South Korea Antibody Drug Conjugates Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
